From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1982
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 1.71
Pain Relevance 0.48

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (HRH2) signal transducer activity (HRH2)
HRH2 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 3 100.00 Very High Very High Very High
cINOD 1 100.00 Very High Very High Very High
Calcium channel 1 99.28 Very High Very High Very High
peptic ulcer disease 2 99.16 Very High Very High Very High
gABA 1 18.72 Low Low
Hyperalgesia 2 5.00 Very Low Very Low Very Low
depression 1 5.00 Very Low Very Low Very Low
antidepressant 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
INFLAMMATION 1 100.00 Very High Very High Very High
Gastroesophageal Reflux Disease 89 99.96 Very High Very High Very High
Ulcers 2 99.16 Very High Very High Very High
Disease 4 98.64 Very High Very High Very High
Cancer 1 87.76 High High
Cardiovascular Disease 1 87.12 High High
Asthma 2 85.20 High High
Convulsion 1 84.56 Quite High
Acid Reflux 7 76.96 Quite High
Sleep Disorders 13 50.00 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
[Newly developed H2-receptor antagonists in the treatment of peptic ulcer disease].
Negative_regulation (developed) of Gene_expression (antagonists) of H2-receptor associated with peptic ulcer disease, antagonist and disease
1) Confidence 0.43 Published 1982 Journal Wien Med Wochenschr Section Title Doc Link 6126962 Disease Relevance 0.37 Pain Relevance 0.28
Therapeutic substitutions are only permitted in a limited number of drug classes: histamine 2 receptor blockers, non-steroidal anti-inflammatory drugs, nitrates, angiotensin converting enzyme inhibitors, dihydropyridine calcium channel blockers and proton pump inhibitors.
Negative_regulation (inhibitors) of Gene_expression (blockers) of histamine 2 receptor associated with inflammation, calcium channel and cinod
2) Confidence 0.10 Published 2010 Journal BMC Health Serv Res Section Body Doc Link PMC2994856 Disease Relevance 0.44 Pain Relevance 0.15
Another study suggested that the addition of a nocturnal H2RA (histamine-2 receptor antagonist) or PPI after taking a morning dose of PPI decreased nocturnal acid breakthrough with improvement of daytime functioning.50 Unfortunately, other data suggested tachyphylaxis with H2RAs in nocturnal acid breakthrough.51
Negative_regulation (decreased) of Gene_expression (addition) of histamine-2 receptor associated with antagonist and gastroesophageal reflux disease
3) Confidence 0.05 Published 2010 Journal Journal of Neurogastroenterology and Motility Section Body Doc Link PMC2879818 Disease Relevance 0.90 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools